99060 74-1
IPDL COPY

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/28

A1

(11) International Publication Number: WO 98/56406

(43) International Publication Date: 17 December 1998 (17.12.98)

(21) International Application Number: PCT/US98/12218

(22) International Filing Date: 11 June 1998 (11.06.98)

(30) Priority Data:
60/053,089 13 June 1997 (13.06.97) US

(71) Applicant *(for all designated States except US)*: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: DEFELIPPIS, Michael, Rosario [US/US]; 10906 Santa Anita Court, Indianapolis, IN 46280 (US). DOBBINS, Michael, Allen [US/US]; 1109 Barry Drive, Lebanon, IN 46052 (US). FRANK, Bruce, Hill [US/US]; 9377 Spring Forest Drive, Indianapolis, IN 46260 (US). LI, Shun [US/US]; 7620 Bancaster Drive, Indianapolis, IN 46268 (US). REBHUN, Dawn, Marie [US/US]; 619 Spring Valley Drive, Indianapolis, IN 46231 (US).

(74) Agents: CALTRIDER, Steven, P. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: STABLE INSULIN FORMULATIONS

(57) Abstract

The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.